Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
---|---|---|---|---|
92206 | Pyrrolidin-1-yl-acetic acid hydrochloride | 6628-74-6 | 98% | |
Coming soon! | ||||
91806 | phenyl 2-(benzyloxy)-3-(dibenzylamino)-5-fluoro-6-methylbenzoate | 1253799-29-9 | 98% | |
Coming soon! | ||||
91409 | 3-Piperazinobenzisothiazole Hydrochloride | 144010-02-6 | 98% | |
The related APILurasidone hydrochlorideThe related intermediates4-(1,2-Benzothiazol-3 | ||||
91408 | 3-(1-Piperazinyl)-1,2-Benzisothiazole | 87691-87-0 | 98% | |
The related APILurasidone hydrochlorideThe related intermediates4-(1,2-Benzothiazol-3 | ||||
90709 | 3-(4-phenoxyphenyl)propanoic acid | 20062-91-3 | 98% | |
Coming soon! | ||||
82406 | PFI-4 | 900305-37-5 | 98% | |
PFI-4 is a potent and selective BRPF1 bromodomain inhibitor (IC50 = 80 nM). Exhibits | ||||
81821 | Piperazin-2-ylmethanol dihydrochloride | 122323-87-9 | 98% | |
Coming soon! | ||||
81817 | Piperazine-2-Carboxylic Acid Methyl Ester Dihydrochloride | 122323-88-0 | 98% | |
Coming soon! | ||||
81814 | Piperazine-2-carboxylic acid dihydrochloride | 3022-15-9 | 98% | |
Coming soon! | ||||
81302 | Pimecrolimus | 137071-32-0 | 98% | |
Pimecrolimus is an immunophilin ligand, which binds specifically to the cytosolic rec | ||||
81301 | Pitavastatin Calcium | 147526-32-7 | 98% | |
Pitavastatin is a member of the blood cholesterol lowering medication class of statin | ||||
73109 | PKI-587 | 1197160-78-3 | 97% | |
PKI-587 is a potent inhibitor to PI3K-, PI3K-, and mTOR (FRAP) with IC50 of 0.4 nM, 5 | ||||
52824 | PFK-015 | 4382-63-2 | 98% | |
PFK-015 is an effective inhibitor of PFKFB3 with IC50 of 110 nM (recombinant PFKFB3) | ||||
52817 | Pramiracetam | 68497-62-1 | 98% | |
Pramiracetam is a nootropic drug derived from piracetam, and is more potent. Pramirac | ||||
52816 | PF-573228 | 869288-64-2 | 98% | |
PF-573228 is a potent and selective FAK inhibitor with IC50 of 4 nM for inhibiton of | ||||
52815 | Paromomycin Sulfate | 1263-89-4 | 98% | |
Paromomycin Sulfate is an aminoglycoside antibiotics inhibiting protein synthesis in | ||||
52756 | PLX647 | 873786-09-5 | 98% | |
PLX647 is a highly specific dual FMS/KIT kinase inhibitor with IC50 of 28/16 nM respe | ||||
52753 | Pexidartinib | 1029044-16-3 | 98% | |
pexidartinib is acapsule formulation containing a small-molecule receptor tyrosine ki | ||||
52740 | PF-543 | 1415562-82-1 | 98% | |
PF-543 is a novel cell-permeant inhibitor of SphK1 with a Ki of 3.6 nM, PF-543 is sph | ||||
52718 | PSI-7977 | 1190307-88-0 | 98% | |
PSI-7977(sofosbuvir) is an investigational nucleotide analog for treatment of chronic | ||||
52701 | Pirfenidone | 53179-13-8 | 98% | |
Pirfenidone(AMR69) is an inhibitor for TGF- production and TGF- stimulated collagen p | ||||
52634 | Poziotinib | 1092364-38-9 | 98% | |
Poziotinib(NOV120101; HM781-36B) is an irreversible Pan-HER inhibitor with IC50s of 3 | ||||
52631 | PF-4708671 | 1255517-76-0 | 98% | |
PF-4708671 is a novel cell-permeable inhibitor of S6K1 (p70 ribosomal S6 kinase 1), w | ||||
52613 | Perifosine | 157716-52-4 | 98% | |
Perifosine (KRX-0401; D-21266; NSC 639966) is a novel Akt inhibitor with IC50 of 4.7 | ||||
52603 | Plinabulin | 714272-27-2 | 98% | |
Plinabulin (NPI-2358) is a vascular disrupting agents (VDA) against tubulin-depolymer | ||||
52592 | PLX-4720 | 918505-84-7 | 98% | |
PLX 4720 is a potent and selective inhibitor of B-RafV600E(IC50=13 nM) and c-Raf-1Y34 | ||||
52591 | Palomid 529 | 914913-88-5 | 98% | |
Palomid 529 (P529) is a novel potent inhibitor of both the mTORC1 and mTORC2 complexe | ||||
52583 | PHT-427 | 1191951-57-1 | 98% | |
PHT-427 is a dual Akt and PDPK1 inhibitor (high affinity binding for the PH domains o | ||||
52564 | Purvalanol A | 212844-53-6 | 98% | |
Purvalanol A(NG-60) is a potent, cell-permeable, and selective inhibitor of cyclin-de | ||||
52560 | PI3K-IN-1 | 1349796-36-6 | 98% | |
PI3K-IN-1 is a potent inhibitor of PI3K, more information can be found in patent WO20 |
Overnight Delivery
Fast & Safe Delivery Worldwide
Safety and Security
Intimate Service
Copyright 2015-2022 武汉永璨生物科技有限公司 版权所有 | 鄂ICP备17005301号-1